Non-Muscle Invasive Bladder Cancer: Expert Guidance for Advanced Practice Providers Webcast (2024)
COMPLIMENTARY CME WEBCAST!
Non-Muscle Invasive Bladder Cancer: Expert Guidance for APPs (2024) is tailored specifically for APPs and features an expert multidisciplinary panel engaging in a dynamic discussion on the latest breakthroughs and strategies in NMIBC management. Don’t miss this chance to elevate your expertise in this critical field. Stream Now!
Expert Faculty:
- Moderator: Mariia Anosova-Smith, CRNP, FNPC
- Panelists: Elena Dreyzin, PA-C; Terran Sims, MSN, ACNP-C, CNNe, COCN; Hong Truong, MD, MS
Acknowledgements
Support provided by independent educational grants from:
- ImmunityBio, Inc.
- Merck & Co., Inc.
- UroGen Pharma, Inc.
Target Audience
- Advanced Practice Providers
Learning Objectives
After participating in this CME activity, participants will be able to:
- Identify the epidemiology, risk factors, and typical clinical presentation of NMIBC.
- Apply the recommended surveillance protocols for patients with low, intermediate, and high risk NMIBC, including frequency and types of follow-up examinations.
- Explain the impact of NMIBC and its treatments on patients' quality of life.
- Employ strategies to mitigate adverse effects related to NMIBC.
- Explore innovative approaches in development for the diagnosis and treatment of NMIBC.
Faculty disclosures posted here prior to webcast release
EDUCATION COUNCIL DISCLOSURE
Education Council Disclosures_June 2024.pdf
COI REVIEW WORK GROUP DISCLOSURES
COI Review Workgroup Disclosures_June 2024.pdf
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
AUA ACCREDITATION INFORMATION
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 1.50 hours
Release Date: December, 2024
Expiration Date: December, 2025
ACCREDITATION:
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION:
The American Urological Association designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER LEARNERS:
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.
MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA PARTICIPANT INFORMATION & POLICIES
DISCLAIMER:
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
REPRODUCTION PERMISSION:
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Non-Physician Participation